Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Rosnilimab by AnaptysBio for Ulcerative Colitis: Likelihood of Approval
Rosnilimab is under clinical development by AnaptysBio and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II...
Data Insights
Rosnilimab by AnaptysBio for Rheumatoid Arthritis: Likelihood of Approval
Rosnilimab is under clinical development by AnaptysBio and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II...